Analysts See Potential Upside for FNX and Key Holdings

Recent analysis reveals that the First Trust Mid Cap Core AlphaDEX Fund ETF (FNX) could see a substantial upside in its price, driven by its underlying holdings, including Axsome Therapeutics, Zeta Global Holdings, and Revolution Medicines, which display notable analyst price target optimism.

Date: 23-10-2024

AI Rating: 7

The report highlights that the First Trust Mid Cap Core AlphaDEX Fund ETF (FNX) is currently priced at $117.00, with analysts projecting a target price of $128.75, suggesting an upside of 10.04%. This bullish outlook is bolstered by positive evaluations of three key holdings: Axsome Therapeutics Inc (AXSM), Zeta Global Holdings Corp (ZETA), and Revolution Medicines Inc (RVMD).

AXSM currently trades at $92.39 but has a significant 36.24% upside to the analyst target of $125.88. Similarly, ZETA's recent price of $26.40 indicates a 32.58% upside based on the target price of $35.00. RVMD, priced at $47.13, also has a 26.55% upside to an average target of $59.64. This projected growth across the board suggests a generally positive sentiment from analysts regarding these stocks.

Although these targets may indicate optimism, they could also signal potential overvaluation if recent developments in the companies and the industry are not adequately reflected in the forecasts. Therefore, investors must proceed with caution and conduct their own research into the fundamentals behind these price targets.

Stocks: FNX AXSM ZETA RVMD